Literature DB >> 16936777

Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors.

K Jong1, E Marchiori, A van der Vaart, S-F Chin, B Carvalho, M Tijssen, P P Eijk, P van den Ijssel, H Grabsch, P Quirke, J J Oudejans, G A Meijer, C Caldas, B Ylstra.   

Abstract

A series of studies have been published that evaluate the chromosomal copy number changes of different tumor classes using array comparative genomic hybridization (array CGH); however, the chromosomal aberrations that distinguish the different tumor classes have not been fully characterized. Therefore, we performed a meta-analysis of different array CGH data sets in an attempt to classify samples tested across different platforms. As opposed to RNA expression, a common reference is used in dual channel CGH arrays: normal human DNA, theoretically facilitating cross-platform analysis. To this aim, cell line and primary cancer data sets from three different dual channel array CGH platforms obtained by four different institutes were integrated. The cell line data were used to develop preprocessing methods, which performed noise reduction and transformed samples into a common format. The transformed array CGH profiles allowed perfect clustering by cell line, but importantly not by platform or institute. The same preprocessing procedures used for the cell line data were applied to data from 373 primary tumors profiled by array CGH, including controls. Results indicated that there is no apparent feature related to the institute or platform and that array CGH allows for unambiguous cross-platform meta-analysis. Major clusters with common tissue origin were identified. Interestingly, tumors of hematopoietic and mesenchymal origins cluster separately from tumors of epithelial origin. Therefore, it can be concluded that chromosomal aberrations of tumors from hematopoietic and mesenchymal origin versus tumors of epithelial origin are distinct, and these differences can be picked up by meta-analysis of array CGH data. This suggests the possibility of prospectively using combined analysis of diverse copy number data sets for cancer subtype classification.

Entities:  

Mesh:

Year:  2006        PMID: 16936777     DOI: 10.1038/sj.onc.1209919

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity.

Authors:  Elisa Närvä; Reija Autio; Nelly Rahkonen; Lingjia Kong; Neil Harrison; Danny Kitsberg; Lodovica Borghese; Joseph Itskovitz-Eldor; Omid Rasool; Petr Dvorak; Outi Hovatta; Timo Otonkoski; Timo Tuuri; Wei Cui; Oliver Brüstle; Duncan Baker; Edna Maltby; Harry D Moore; Nissim Benvenisty; Peter W Andrews; Olli Yli-Harja; Riitta Lahesmaa
Journal:  Nat Biotechnol       Date:  2010-03-28       Impact factor: 54.908

2.  Battling cancer on many fronts. Meeting on New Battlefields in Human Cancer--Attacking in Many Fronts.

Authors:  Fabian Zanella; Amancio Carnero
Journal:  EMBO Rep       Date:  2008-09       Impact factor: 8.807

3.  Detection limits of DNA copy number alterations in heterogeneous cell populations.

Authors:  Oscar Krijgsman; Daniëlle Israeli; Hendrik F van Essen; Paul P Eijk; Michel L M Berens; Clemens H M Mellink; Aggie W Nieuwint; Marjan M Weiss; Renske D M Steenbergen; Gerrit A Meijer; Bauke Ylstra
Journal:  Cell Oncol (Dordr)       Date:  2012-11-02       Impact factor: 6.730

4.  Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas.

Authors:  Gayatry Mohapatra; David A Engler; Kristen D Starbuck; James C Kim; Derek C Bernay; George A Scangas; Audrey Rousseau; Tracy T Batchelor; Rebecca A Betensky; David N Louis
Journal:  Acta Neuropathol       Date:  2010-11-16       Impact factor: 17.088

5.  Identification of recurrent regions of Copy-Number Variants across multiple individuals.

Authors:  Teo Shu Mei; Agus Salim; Stefano Calza; Ku Chee Seng; Chia Kee Seng; Yudi Pawitan
Journal:  BMC Bioinformatics       Date:  2010-03-22       Impact factor: 3.169

6.  An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models.

Authors:  Xin Lu; Ke Zhang; Charles Van Sant; John Coon; Dimitri Semizarov
Journal:  BMC Med Genomics       Date:  2010-06-22       Impact factor: 3.063

7.  Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

Authors:  Martin L Sos; Kathrin Michel; Thomas Zander; Jonathan Weiss; Peter Frommolt; Martin Peifer; Danan Li; Roland Ullrich; Mirjam Koker; Florian Fischer; Takeshi Shimamura; Daniel Rauh; Craig Mermel; Stefanie Fischer; Isabel Stückrath; Stefanie Heynck; Rameen Beroukhim; William Lin; Wendy Winckler; Kinjal Shah; Thomas LaFramboise; Whei F Moriarty; Megan Hanna; Laura Tolosi; Jörg Rahnenführer; Roel Verhaak; Derek Chiang; Gad Getz; Martin Hellmich; Jürgen Wolf; Luc Girard; Michael Peyton; Barbara A Weir; Tzu-Hsiu Chen; Heidi Greulich; Jordi Barretina; Geoffrey I Shapiro; Levi A Garraway; Adi F Gazdar; John D Minna; Matthew Meyerson; Kwok-Kin Wong; Roman K Thomas
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

8.  Integrative analysis reveals the direct and indirect interactions between DNA copy number aberrations and gene expression changes.

Authors:  Hyunju Lee; Sek Won Kong; Peter J Park
Journal:  Bioinformatics       Date:  2008-02-08       Impact factor: 6.937

9.  Normalized, segmented or called aCGH data?

Authors:  Wessel N van Wieringen; Mark A van de Wiel; Bauke Ylstra
Journal:  Cancer Inform       Date:  2007-09-17

10.  Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down.

Authors:  José L Costa; Paul P Eijk; Mark A van de Wiel; Derk ten Berge; Fernando Schmitt; Carmen J Narvaez; JoEllen Welsh; Bauke Ylstra
Journal:  BMC Genomics       Date:  2009-10-28       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.